Clinical Trial Update: Safety of NNC 0123-0000-0338 in Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 safety assessment of the compound NNC 0123-0000-0338 in healthy subjects, conducted by Novo Nordisk, has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes

Drugs mentioned

• NNC 0123-0000-0338

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Healthy | Phase 1 | Status: COMPLETED